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Ventilator-associated pneumonia (VAP)Major concern for intubated patients is ventilator-associated pneumonia (VAP). Early detection of VAP and its
causative microorganism(s) is a key challenge for clinicians. Diagnosis is based on clinical, radiological, and mi-
crobiological elements, the latter being provided 24–48 h after sampling. According to practices, clinicians can
sample endotracheal aspirates (ETAs) so as to check for patient colonization or perform ETA in case of VAP sus-
picion. In this proof-of-concept study, we report the evaluation of a semiautomatedmolecularmethod to rapidly
quantify Staphylococcus aureus, one of themost involvedmicroorganisms in VAP, directly from raw ETA samples.
After evaluation using artiﬁcial ETA samples, our method was applied on 40 clinical ETA samples. All S. aureus–
positive samples were successfully detected and quantiﬁed. Our method can provide an efﬁcient sample prepa-
ration protocol for all raw ETA samples, combined with an accurate quantiﬁcation of the bacterial load, in less
than 3 h 30 min.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Major concern for intubated patients is ventilator-associated pneu-
monia (VAP). VAP is deﬁned as a pneumonia that occurs in critically ill
patients under mechanical ventilation for at least 48 h (Chastre and
Fagon, 2002; Koenig and Truwit, 2006). VAP is traditionally reported
as the most frequent nosocomial infection in critically ill patients and
is associated with signiﬁcant morbidity and mortality (Barbier et al.,
2013; Melsen et al., 2013). VAP prolongs the duration of ventilation,
the duration of ICU and hospital stays, and results in additional hospital
costs (Restrepo et al., 2010; Safdar et al., 2005).
Diagnosis of VAP is based on clinical, radiological, and biological ele-
ments (Nair and Niederman, 2014). VAP occurs after initial colonization
of the respiratory tract by a microorganism. Early detection of VAP and
its causative microorganism(s) is a key challenge for clinicians whose
aim is to establish a rapid and adapted antibiotic therapy. According to
practices, clinicians can sample endotracheal aspirates (ETAs) so as to
check for patient colonization or perform bronchoalveolar lavages
(BALs) or ETA in case of VAP suspicion (Luna et al., 2014; Michel et al.,
2005; Scholte et al., 2014). Although BAL is considered as the goldax: +33-0478-875-340.
(V. Moucadel).
. This is an open access article understandard method to diagnose VAP, this procedure is invasive and re-
quires a clinician. On the other hand, ETA can be sampled by nurses
and is noninvasive and cheaper.
Nowadays, identiﬁcation of the causative microorganism(s) relies
on quantitative or semiquantitative cultures of BAL or ETA with micro-
biological data provided 24–48 h after the sampling (File, 2010; Koenig
and Truwit, 2006). Previous studies have already shown the use and in-
terest of molecular tools to provide shorter microbiological evidence,
but they mainly focused on BAL due to their easier analytical manage-
ment (Apfalter et al., 2005; Rios-Licea et al., 2010). In this proof-of-
concept study, we report the evaluation of a semiautomated molecular
method to rapidly quantify Staphylococcus aureus, the most involved
microorganisms in VAP (Restrepo et al., 2013), directly from ETA sam-
ples. After evaluation of themethod on artiﬁcial ETA samples, ourmeth-
od was then applied on a wide range of clinical ETA samples.
2. Materials and methods
2.1. ETA samples
For artiﬁcial ETA, we used a solution adapted from Sriramulu et al.
(2005) composed of 0.5% mucin, 0.4 g herring sperm DNA/100 mL, 0.5 g/
100 mL NaCl, 0.22 g/100 mL KCl (Sigma Aldrich, Saint-Quentin Fallavier,
France), and0.5mL/100mLegg yolk emulsion (Oxoid SA,Dardilly, France).the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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the medical intensive care unit (ICU) of Limoges University Hospital
(France) over an 8-month period (January–August 2012). Patients
who had been under mechanical ventilation for at least 48 h were in-
cluded. A written information was given to the patients or their legally
authorized representative prior to enrollment as required by French
law for biological collections of leftovers. ETA samples were collected
under aseptic conditions until VAP, extubation, or patient death oc-
curred. A part of ETAwas used for conventionalmicrobiological analysis,
and the leftover was frozen at−80 °C for molecular analysis. All molec-
ular analyzeswere performed by batch, 1month after the end of the last
sample collection. When culture of at least 1 ETA was positive for S. au-
reus (≥103 CFU/mL) over the time of follow-up, all ETA samples of the
patient were kept for molecular analysis.
2.2. Microbiological procedures
Microbiological analysis of ETA was performed as recommended by
the European Society for Clinical Microbiology and Infectious Diseases so-
ciety (http://www.escmid.org/escmid_library/manual_of_microbiology).
ETAs were treated with Digest-EUR (V/V) (Eurobio®, Courtaboeuf,
France) and mixed by vortex with glass beads. One hundred microliters
was diluted into 1 mL of sterile saline solution, and 10 μL of this suspen-
sion was seeded on COS, Cled, CAP (Oxoid), and Haem (bioMérieux)
agar plates incubated at 37 °C for 48 h. Dilutions were so performed so
as to obtain a detection threshold of 103 CFU/mL and amaximumquanti-
ﬁcation of 106 CFU/mL. All visible bacteria, including bacteria from oro-
pharyngeal ﬂora, were quantiﬁed. Bacterial identiﬁcation was
performed with the Vitek2 system (bioMérieux SA).
2.3. Molecular quantiﬁcation of S. aureus from ETA samples
Fourhundredmicroliters of ETAwas incubated for 10min at 37 °Cwith
48 μL DNAse buffer 10× and 35 U of RQ1 RNase-free DNAse (Promega,
Lyon, France). Digest-EUR (v/v) and 5 μg lysin (Hyglos GmbH, Bernried,
Germany)were then added for incubation for 15min at 37 °Cwith vortex
every 5 min. Lysates were ﬁnally extracted applying the EasyMAG®
(bioMérieux) Protocol B2.0.1 with an elution volume of 55 μL.
Real-time PCR (qPCR) were run using the ABI7500FastDx PCR instru-
ment (Life Technologies, Saint Aubin, France). Each qPCR was performed
from 2-μL easyMAG® eluate using the FastStart Taq DNA polymerase
(Roche,Meylan, France), as recommendedby themanufacturer. Theprimers
(CACCTGCTGCAAATGCTG and CGTTGATCAGCGTTTAAGTTAGGCATATT)
and TaqMan probe (CGCAACACGATGAAGCTCAACAAAATGC) targeted the
spa gene of S. aureus. PCR programwas 10min activation at 95 °C, followed
by40cyclesofdenaturationat95 °C for30s, annealing/extensionat60 °C for
1 min.
Analytical performancewas determined using 300 μL of artiﬁcial ETA
spiked with 100 μL of serial dilutions of a clinical S. aureus strain
(bioMérieux collection), starting from a 0.5 McFarland calibrated sus-
pension. The spiked bacterial quantities were determinedmore precise-
ly by plating the dilutions. For sensitivity, 3 replicates for 4 high
concentrations and 8 replicates for 6 low concentrations were tested
(Table S1). The limit of detection (LOD)was deﬁned as the lowest quan-
tity per sample for which all 8 replicates were detected. For clinical ETA
samples, cycle threshold (Ct) results were converted to CFU/mL using
the standard curve generated during the evaluation of the LOD.
3. Results and discussion
In the present study,we report the evaluation of amolecularmethod
able to rapidly and easily quantify S. aureus directly from raw ETA sam-
ples collected from intubated patients. Themethod is partially automat-
ed and uses the easyMAG® system for nucleic acid extraction and a
qPCR platform for the quantiﬁcation of S. aureus.The main difﬁculty that we had to circumvent was the viscosity and
the heterogeneity of ETA samples. To this end, we optimized a 30-min
prelysis step before nucleic acid extraction. This step, described in the
Materials and methods section, was essential to liquefy and lyse all
raw ETA samples. It ensured the efﬁcient recovery of DNA. Indeed, the
presence of remaining clusters may impact the accuracy of the quantiﬁ-
cation. Using this combined approach (liquefaction and prelysis), all the
clinical ETA samples were successfully processed despite their diverse
macroscopic aspects (viscous, purulent, bloody), their microbiology
contents (mono or polymicrobial), and the concomitant antibiotherapy
(quinolones, beta-lactams…) at the time of sampling (Table 1).
Analytical performance was ﬁrst determined with artiﬁcial ETA
spiked with different concentrations of S. aureus. The LOD was below
103 CFU/sample (980 CFU), and the upper limit of quantiﬁcation was
close to 107 CFU/sample (8.1 106 CFU) with an efﬁciency of 94.7%
(Table S1). We so decided to present quantitative molecular results
from103 CFU/mL to 106 CFU/mL. Results outside this rangewere reported
b103 and N106 CFU/mL. The dynamic range for quantiﬁcation, from103 to
106 CFU/mL, was compatible with the conventional culture and the clini-
cal requirements. These data are in agreementwith the diagnostic thresh-
olds used for ETA, i.e., 105–106 CFU/mL (Torres et al., 2006).
The method was tested using 40 different clinical ETA samples
collected from 11 ventilated patients. Days of sampling, appearance
of the samples, microbiology report, use of antibiotics at the time of
the sampling, and qPCR results are reported in Table 1. S. aureus–
positive and S. aureus–negative culture results were conﬁrmed by
qPCR, whatever the macroscopic appearance of ETA and the pres-
ence and the quantities of other commensal or pathogenic bacteria
observed by culture. For patients 1, 3, 5, and 9 who did not receive
antibiotics, both the semiquantitative culture and the molecular
methods showed an increase of the S. aureus quantiﬁcations over
time. For patients 2, 6, 7, and 11 who were treated with adapted an-
tibiotics, both the semiquantitative culture and the qPCR method
showed a decrease of the bacterial quantiﬁcation overtime. In 2 dif-
ferent cases, the qPCR detected S. aureuswhen the conventionalmeth-
odwas negative; ﬁrst, when the culture became positive on the day after,
e.g., patients 1 and 9; second, when the patient was treated with an anti-
biotic, e.g., patients 2 and 11. These 2 cases show that our method does
not generate false-positive results.
Globally, quantiﬁcation from molecular results was slightly higher
than quantiﬁcation from culture with a delta close to 1 log. Several hy-
potheses can explain this: i)ﬁrst, contrary towhat is currently admitted,
the semiquantiﬁcation culture is not the perfect “gold standard”. This
conventional technique is still manual with several variations that
may occur during the digestion process (volume of the digestion re-
agent is difﬁcult to adjust, insufﬁcient digestion, and remaining clus-
ters), during the dilution process, during the seeding, and also during
the quantiﬁcation (visual subjective reading); ii) the volume of sam-
pling differs according to the method. Indeed, with the conventional
method, only 10 μL of a digested ETA sample is used versus 400 μL of a
raw ETA sample with the molecular process, a volumemuchmore rep-
resentative; iii) the competition for the culture between the different
bacteria can also inﬂuence the quantiﬁcation; it is notably the case
when S. aureus is at low concentrations mixed with other pathogenic
or commensal bacteria present at higher concentrations; iv) contrary
to the conventional method, the molecular method is able to detect
DNA from nonviable bacteria and thus overestimates quantities of
CFU/mL. This is particularly the case when the patient is treated by an-
tibiotics; v) lastly, the qPCR is probably amore sensitivemethod as pre-
viously reported by other authors (Apfalter et al., 2005). These
discrepancies between the quantiﬁcations from culture and from the
molecular method were previously observed in the literature for other
types of respiratory specimens and were attributed to the manual pro-
cess of DNA extraction and the presence of blood in samples (Rios-
Licea et al., 2010). Our results showed high reproducibility, and the
presence of blood had no negative impact on the quantiﬁcation.
Table 1
Clinical ETA samples: quantiﬁcation of S. aureuswith the semiquantitative culture and the molecular methods.
Patient Day of
sampling
Appearance
of ETA
Antibiotics on
sampling day
S. aureus
(CFU/mL)
Other microorganisms (CFU/mL) Ct S. aureus
(estimated CFU/mL)
1 1 Purulent No b103 α-Hemolytic Streptococcus spp. (103),
Haemophilus parainﬂuenzae (104)
30.7 3.103
2 Purulent, bloody No 104 α-Hemolytic Streptococcus spp. (103) 23.4 3.105
3 Purulent No 106 H. parainﬂuenzae (106) 11.2 N106
4 purulent No N106 α-Hemolytic Streptococcus spp. (103),
H. parainﬂuenzae (104), Neisseria spp. (104),
Aggregatibacter spp. (103), Eikenella corrodens (103)
15.3 N106
6 Bloody No N106 H. parainﬂuenzae (106), Aggregatibacter spp. (103) 14.3 N106
2 1 Purulent FOS + OXA 105 Enterococcus faecalis (105),
Corynebacterium striatum (104),
Staphylococcus epidermidis (104)
21.8 N106
2 Purulent FOS + OXA 103 No other microorganism 25.9 8.105
3 Purulent OXA 104 Enterococcus faecalis (104),
Corynebacterium striatum (104),
α-hemolytic Streptococcus spp. (103)
27.5 2.105
4 Purulent OXA 104 Aspergillus spp. (103), Lactobacillus spp. (104),
Corynebacterium spp. (104)
27.0 1.105
5 Purulent OXA 103 Aspergillus spp. (103), yeast (103) 31.8 4.103
6 Purulent OXA b103 Yeast (103) 30.4 1.104
7 Purulent OXA b103 Corynebacterium spp. (104),
α-hemolytic Streptococcus spp. (103)
28.7 3.104
8 White foam OXA b103 CoNS (103), yeast (103) N40 b103
3 1 Purulent No b103 Neisseria subﬂava (N106), Rothia mucilaginosa (103),
nonhemolytic Streptococcus spp. (N106)
36.0 b103
3 Purulent No b103 N. subﬂava (106), nonhemolytic
Streptococcus spp. (106), yeast (103), S. epidermidis (104)
34.9 b103
5 Purulent No 104 N. subﬂava (106) 22.6 N106
4 1 Bloody No 106 Streptococcus constellatus (N106), Neisseria spp. (105),
α-hemolytic Streptococcus spp. (103),
H. parainﬂuenzae (105), Klebsiella oxytoca (104)
20.3 N106
2 Purulent AMC 105 S. constellatus (105), H. parainﬂuenzae (103) 21.0 N106
3 Purulent, bloody AMC 105 No other microorganism 19.7 N106
5 1 Viscous No 104 Neisseria spp. (105), Rothia mucilaginosa (104),
nonhemolytic Streptococcus sp (105),
Haemophilus haemolyticus (105)
25.0 4.105
2 Bloody No 106 α-Hemolytic Streptococcus spp. (103),
Proteus mirabilis (104)
13.5 N106
3 Purulent No N106 P. mirabilis (104) 14.6 N106
4 Purulent No N106 P. mirabilis (105) 16.7 N106
6 2 Purulent No N106 Haemophilus inﬂuenzae (104), Escherichia coli (104) 17.2 N106
5 Purulent OFX + OXA 104 No other microorganism 22.0 N106
7 Purulent OFX + OXA 105 α-Hemolytic Streptococcus spp. (105) 27.1 5.105
7 1 Purulent No 104 α-Hemolytic Streptococcus spp. (104) 23.5 N106
2 Purulent No 106 No other microorganism 17.4 N106
3 Purulent No 105 No other microorganism 20.3 N106
4 Purulent CRO + OFX + OXA 103 E. faecalis (103), Corynebacterium spp. (103),
α-hemolytic Streptococcus spp. (104),
S. epidermidis (103), P. mirabilis (103)
26.8 6.105
5 Purulent CRO + OFX + OXA b103 E. faecalis (103), S. epidermidis (103),
Pseudomonas aeruginosa (104)
37.5 b103
8 3 Purulent No 105 α-Hemolytic Streptococcus spp. (106),
CoNS (104), Neisseria spp. (104),
Aggregatibacter spp. (104)
26.2 1.106
4 Purulent No 106 α-Hemolytic Streptococcus sp (106),
CoNS (103), Neisseria sp (105),
Aggregatibacter spp. (106)
24.1 N106
9 4 Purulent No b103 Corynebacterium pseudodiphteriticum (N106),
Rothia mucilaginosa (103)
35.8 2.103
6 Purulent No 103 Corynebacterium spp. (106), Neisseria spp. (103) 33.0 2.104
7 Purulent No 104 Corynebacterium spp. (N106),
H. parainﬂuenzae (103), H. inﬂuenzae (103),
α-hemolytic Streptococcus spp. (104)
29.4 2.105
10 1 Purulent No N106 H. inﬂuenzae (105), Neisseria spp. (104),
Aggregatibacter spp. (104)
16.0 N106
11 1 Purulent No 103 Streptococcus pneumoniae (106),
H. parainﬂuenzae (105), α-hemolytic
Streptococcus spp. (106), Neisseria spp. (103),
CoNS (104), Enterobacter cloacae (104)
31.2 4.104
3 Purulent AMC b103 No other microorganism 26.4 8.105
4 Purulent AMC b103 No other microorganism 27.8 3.105
FOS = fosfomycin; OXA = oxacillin; AMC = amoxicillin, clavulanic acid; OFX = oﬂoxacin; CRO = ceftriaxone; CoNS = coagulase-negative Staphylococcus spp.
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Schulte et al., 2014), the 2 main added values of ours are i) its ability
to extract DNA from ETA samples and ii) its ability to obtain a quantiﬁ-
cation of the microorganism in CFU/mL. This study was designed for S.
aureus, but it can be easily transposed to other microorganisms. Never-
theless, our molecular method has some limitations. First, this study is
monocentric with only 11 patients despite 40 ETA samples with a
wide diversity of aspect and composition. Second, addition of a speci-
men processing control at the beginning of the protocol would allow
to assess the extraction DNA and the PCR during the process. Finally,
the complete automation of the methods would be an asset to reduce
hands on time and time to result.
4. Conclusion
We optimized a molecular method to quantify S. aureus directly
from ETA samples, in less than 3 h 30 min. The strength of our method
is to provide an efﬁcient sample preparation protocol for all raw ETA,
combined with an accurate quantiﬁcation of the bacterial load. We
have focused our study on S. aureus; however, our method is ﬂexible
and can be adapted to other pathogens involved in VAP and also antibi-
otic resistance genes. Further clinical studies have now to be undertaken
to investigate the medical impact of this method in the predictive diag-
nostic of VAP.
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